# Haya Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/haya-therapeutics

- Industry: Biotechnology
- Headquarters: Lausanne, Switzerland
- Website: www.hayatx.com
- Total disclosed funding: $90M
- Latest round: Series A (May 8, 2025)
- Investors on record: 14

## About

Haya Therapeutics SA, based in Switzerland, develops precision RNA therapies targeting the human genome's dark matter, focusing specifically on regulatory RNAs to address chronic and rare diseases.Founded in 2019 and headquartered in Lausanne, Switzerland, Haya Therapeutics SA specializes in RNA-based therapeutics. The company has successfully completed a total of six deals, with the most recent funding round being a Series A, raising USD 65.000 mn from notable investors, including Sofinnova Partners and Earlybird Venture Capital. The company's leadership includes CEO Samir Ounzain, who is among the founders, alongside Daniel Blessing.Haya Therapeutics specializes in developing precision RNA therapies that target the human genome's dark matter, particularly focusing on long non-coding RNAs (lncRNAs). Their innovative therapeutics are designed to modulate disease-driving cell states, utilizing proprietary tools to identify diseased tissues and cells. The company aims to provide solutions for rare and chronic diseases through emerging modalities, such as engineered antisense oligonucleotides (ASOs). Haya Therapeutics markets its products primarily to biopharmaceutical companies and research institutions in North America and Europe.Haya Therapeutics generates revenue through collaborations with biopharmaceutical companies and research institutions, focusing on B2B transactions. Their revenue structures include licensing agreements, allowing partners to utilize Haya's proprietary technology in drug development. The company's core products, targeting lncRNAs, are positioned for long-term contracts with research institutions and pharmaceutical developers, with pricing plans reflective of the complexity and customization involved in their RNA therapies.In May 2025, Haya Therapeutics SA secured USD 65.000 mn in Series A funding to enhance research and development efforts, particularly advancing clinical trials for its HTX-001 drug targeting heart failure treatment. The company aims to release new products focusing on RNA-targeted therapies while expanding its market presence in North America and Europe. The recent funding will be allocated to support these initiatives and enhance the company's capabilities in addressing unmet medical needs.

## Funding rounds

- Series A, May 8, 2025, $65M — Sofinnova Partners, Alexandria Venture Investments, Earlybird, +ND Capital, Athos Capital, Apollo Health Ventures, Bernina BioInvest AG, Lilly, 4See Ventures, LifeLink Ventures
- Seed, Feb 9, 2022, $5M — Schroders Capital, Broadview Ventures, Apollo Health Ventures, Bernina BioInvest AG, Humboldt Fund, 4See Ventures, Viva BioInnovator
- Seed, May 20, 2021, $20M — Schroders Capital, Broadview Ventures, Apollo Health Ventures, Bernina BioInvest AG, 4See Ventures, Viva BioInnovator
- Seed, Jan 1, 2020 — Broadview Ventures

## Investors

- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Seed
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Seed
- Apollo Health Ventures (https://capitalatlas.ai/funds/apollo-health-ventures) — Seed, Series A
- Bernina BioInvest AG — Seed, Series A
- 4See Ventures (https://capitalatlas.ai/funds/4see-ventures) — Seed, Series A
- Viva BioInnovator (https://capitalatlas.ai/funds/viva-bioinnovator) — Seed
- Humboldt Fund (https://capitalatlas.ai/funds/humboldt-fund) — Seed
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Earlybird (https://capitalatlas.ai/funds/earlybird) — Series A
- +ND Capital (https://capitalatlas.ai/funds/nd-capital) — Series A
- Athos Capital (https://capitalatlas.ai/funds/athos-capital) — Series A
- Lilly — Series A
- LifeLink Ventures — Series A